Histiocytosis and the nervous system: from diagnosis to targeted therapies

F Cohen Aubart, A Idbaih, JF Emile, Z Amoura… - Neuro …, 2021 - academic.oup.com
Histiocytoses are heterogeneous hematopoietic diseases characterized by the accumulation
of CD68 (+) cells with various admixed inflammatory infiltrates. The identification of the …

Rosai–Dorfman disease between proliferation and neoplasia

I Elbaz Younes, L Sokol, L Zhang - Cancers, 2022 - mdpi.com
Simple Summary Rosai–Dorfman disease (RDD) was a benign histiocytic proliferative
disorder rather than a neoplastic process. Emergent molecular studies have shown …

Histiocytic neoplasms, version 2.2021, NCCN clinical practice guidelines in oncology

RS Go, E Jacobsen, R Baiocchi, I Buhtoiarov… - Journal of the National …, 2021 - jnccn.org
Histiocytic neoplasms are rare hematologic disorders accounting for less than 1% of cancers
of the soft tissue and lymph nodes. Clinical presentation and prognosis of these disorders …

Rosai-Dorfman disease displays a unique monocyte-macrophage phenotype characterized by expression of OCT2

A Ravindran, G Goyal, RS Go… - The American Journal of …, 2021 - journals.lww.com
Rosai-Dorfman disease (RDD) is a rare histiocytosis with heterogenous clinical features. In
this study, we characterized the histologic and phenotypic features in 33 RDD patients to …

Outcomes after treatment with cobimetinib in patients with Rosai-Dorfman disease based on KRAS and MEK alteration status

JP Abeykoon, KL Rech, JR Young, A Ravindran… - JAMA …, 2022 - jamanetwork.com
Importance Rosai-Dorfman disease (RDD) is a rare histiocytic neoplasm with recent studies
showing alterations in the MAPK pathway, most commonly in theKRASandMEKgenes in …

Case 30-2024: a 45-year-old woman with kidney lesions and lytic bone disease

LYC Chen, AJ Huang, JH Stone… - New England Journal of …, 2024 - Mass Medical Soc
Case 30-2024: A 45-Year-Old Woman with Kidney Lesions and Lytic Bone Disease | New
England Journal of Medicine Skip to main content The New England Journal of Medicine …

Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C

SN Chi, JS Yi, PM Williams… - JNCI: Journal of the …, 2023 - academic.oup.com
Abstract Background National Cancer Institute-Children's Oncology Group Pediatric
Molecular Analysis for Therapy Choice assigns patients aged 1-21 years with refractory …

Clinical phenotypes, molecular analysis, and outcomes of patients with Rosai-Dorfman disease

L Chang, B Qiao, H Cai, H Lin, M Duan, J Li, D Zhou… - Leukemia, 2023 - nature.com
Rosai-Dorfman disease (RDD) is a rare non Langerhans-cell histiocytosis (LCH) of
unknown etiology [1]. According to the 2016 revised histiocytosis classification, RDD …

Highlights of the management of adult histiocytic disorders: Langerhans cell histiocytosis, Erdheim-Chester disease, Rosai-Dorfman disease, and hemophagocytic …

HA Salama, AR Jazieh, AY Alhejazi, A Absi… - … Myeloma and Leukemia, 2021 - Elsevier
Histiocytic disorders are an exceptionally rare group of diseases with diverse manifestations
and a paucity of approved treatments, thereby leading to various challenges in their …

Recent advances in IgG4-related kidney disease

M Kawano, T Saeki, Y Ubara, S Matsui - Modern Rheumatology, 2023 - academic.oup.com
Recent advances in the management and understanding of immunoglobulin (Ig) G4-related
kidney disease (RKD) have emphasized the importance of urgent treatment in IgG4-related …